Hungary's Olivér Várhelyi readies to be EU health commissioner, pledging major pharma support

Zachary Brennan

Senior Editor

On the heels of her reelection in July, European Commission President Ursula von der Leyen tasked her new commissioner-designate for health and animal welfare with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hungary's Olivér Várhelyi readies to be EU health commissioner, pledging major pharma support

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Revolution Medicines breaks ground in challenging pancreatic cancer with two RAS drugs

Iterum wins approval for new oral antibiotic for UTIs. Now it wants a partner

Elucida Oncology, seeking foothold in ADCs, shutters due to 'lack of funding'

Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson

Post-Hoc: Novo’s obesity enemies

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Hun­gary's Olivér Várhe­lyi read­ies to be EU health com­mis­sion­er, pledg­ing ma­jor phar­ma sup­port

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

Iterum wins ap­proval for new oral an­tibi­ot­ic for UTIs. Now it wants a part­ner

Elu­ci­da On­col­o­gy, seek­ing foothold in AD­Cs, shut­ters due to 'lack of fund­ing'

Chi­nook alums re­unite fol­low­ing ex­it to No­var­tis; The first board ap­point­ment for Re­cur­sion’s Chris Gib­son

Post-Hoc: No­vo’s obe­si­ty en­e­mies

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

Hungary's Olivér Várhelyi readies to be EU health commissioner, pledging major pharma support

Revolution Medicines breaks ground in challenging pancreatic cancer with two RAS drugs

Iterum wins approval for new oral antibiotic for UTIs. Now it wants a partner

Elucida Oncology, seeking foothold in ADCs, shutters due to 'lack of funding'

Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson

Post-Hoc: Novo’s obesity enemies

IDEAYA Biosciences: Targeting unmet market needs with precision oncology